Geron Corporation (GERN)

Market Cap	807.09M
Revenue (ttm)	164.45M
Net Income (ttm)	-88.01M
Shares Out	638.02M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,650,934
Open	1.270
Previous Close	1.240
Day's Range	1.250 - 1.310
52-Week Range	1.090 - 4.500
Beta	0.57
Analysts	Buy
Price Target	3.17 (+150.59%)
Earnings Date	Nov 6, 2025

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.17, which is an increase of 150.59% from the latest price.

Price Target

$3.17

(150.59% upside)

Analyst Consensus: Buy